Alphamab Oncology (9966.HK)

HKD 3.54

(-1.67%)

Net Income Summary of Alphamab Oncology

Alphamab Oncology's latest annual net income in 2023 was -210.59 Million CNY , up 35.35% from previous year.
Alphamab Oncology's latest quarterly net income in 2024 Q2 was -44.89 Million CNY , down 0.0% from previous quarter.
Alphamab Oncology reported an annual net income of -325.72 Million CNY in 2022, up 21.02% from previous year.
Alphamab Oncology reported an annual net income of -412.41 Million CNY in 2021, up 3.59% from previous year.
Alphamab Oncology reported a quarterly net income of -39.86 Million CNY for 2023 Q2, down 0.0% from previous quarter.
Alphamab Oncology reported a quarterly net income of -210.59 Million CNY for 2023 FY, up 35.35% from previous quarter.

Annual Net Income Chart of Alphamab Oncology (2023 - 2017)

Historical Annual Net Income of Alphamab Oncology (2023 - 2017)

Year	Net Income	Net Income Growth
2023	-210.59 Million CNY	35.35%
2022	-325.72 Million CNY	21.02%
2021	-412.41 Million CNY	3.59%
2020	-427.76 Million CNY	48.85%
2019	-836.34 Million CNY	-458.15%
2018	-149.84 Million CNY	-353.23%
2017	-33.06 Million CNY	0.0%

Year	Net Income	Net Income Growth
2024 Q2	-44.89 Million CNY	0.0%
2023 Q2	-39.86 Million CNY	0.0%
2023 FY	-210.59 Million CNY	35.35%
2023 Q4	-170.73 Million CNY	0.0%
2022 Q4	-178.41 Million CNY	0.0%
2022 FY	-325.72 Million CNY	21.02%
2022 Q2	-147.3 Million CNY	0.0%
2021 Q2	-267.36 Million CNY	0.0%
2021 Q4	-145.05 Million CNY	0.0%
2021 FY	-412.41 Million CNY	3.59%
2020 FY	-427.76 Million CNY	48.85%
2020 Q4	-324.66 Million CNY	0.0%
2020 Q2	-103.1 Million CNY	0.0%
2019 FY	-836.34 Million CNY	-458.15%
2019 Q4	-773.95 Million CNY	0.0%
2019 Q2	-58.78 Million CNY	71.88%
2019 Q1	-209.08 Million CNY	-113.59%
2018 Q1	-51.03 Million CNY	0.0%
2018 Q2	-51.95 Million CNY	-1.79%
2018 FY	-149.84 Million CNY	-353.23%
2018 Q4	-97.89 Million CNY	0.0%
2017 Q2	-16.2 Million CNY	0.0%
2017 Q1	-16.2 Million CNY	0.0%
2017 FY	-33.06 Million CNY	0.0%
2017 Q4	-51.03 Million CNY	0.0%
2016 Q4	-16.2 Million CNY	0.0%

Peer Net Income Comparison of Alphamab Oncology

Name	Net Income	Net Income Difference
Uni-Bio Science Group Limited	70.87 Million HKD	397.129%
CK Life Sciences Int'l., (Holdings) Inc.	17.25 Million HKD	1320.829%